EPIGENETIC PCSK9 SILENCING WITH STX-1150 PROVIDES DURABLE LDL-C CONTROL AFTER A SINGLE DOSE

IF 7.1 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Atherosclerosis Pub Date : 2026-08-01 Epub Date: 2026-09-09 DOI:10.1016/j.atherosclerosis.2026.120860

Emeric Charles, Steven Keller, Shyam Bale, Jason Fernandes, Carlos Santamaria, Heather Kozy, Maitreyee Karmarkar, Yuexuan Li, Oleh Krupa, Simon Bucher, Keith Schulwach, Sterling Ripley-Phipps, Natalie Goh, Fred Deiter, Michelle Eggers, Christie Sze, Farah Bardai, Sarah Denny, Benjamin Oakes

引用次数: 0

查看原文本刊更多论文

stx-1150的表观遗传pcsk9沉默在单剂量后提供持久的ldl-c控制

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Atherosclerosis 医学-外周血管病

CiteScore

9.80

自引率

3.80%

发文量

1269

审稿时长

36 days

期刊介绍： Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.